Arvinas to Present at the Citi 15th Annual BioPharma Virtual Conference
Arvinas, a clinical-stage biotechnology company (Nasdaq: ARVN), announced that its Chief Scientific Officer, Ian Taylor, Ph.D., will participate in a fireside chat at the Citi 15th Annual BioPharma Virtual Conference on September 10 at 2:25 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Arvinas, a clinical-stage biotechnology company (Nasdaq: ARVN), announced that its Chief Scientific Officer, Ian Taylor, Ph.D., will participate in a fireside chat at the Citi 15th Annual BioPharma Virtual Conference on September 10 at 2:25 p.m. ET. A live audio webcast will be available here and on Arvinas’ website. The company is focused on developing therapies for diseases like metastatic prostate cancer and ER+/HER2- breast cancer.
Details
News Market Reaction – ARVN
The recorded move for ARVN in the trading session of this news was -1.01%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW HAVEN, Conn., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the Citi 15th Annual BioPharma Virtual Conference on Thursday, September 10 at 2:25 p.m. ET.
A live audio webcast of the presentation will be available here and on Arvinas’ website at www.arvinas.com. A replay of the webcast will be archived on Arvinas’ website for 30 days following the presentation.
About Arvinas
Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. The company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit www.arvinas.com.
Contacts for Arvinas
Investors
Will O’Connor, Stern Investor Relations
ir@arvinas.com
Media
Kirsten Owens, Arvinas Communications
kirsten.owens@arvinas.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.